Press release
Graphene Manufacturing (TSXV: GMG) (OTCQX: GMGMF) Signs Exclusive Global Rail Agreement with Alstom
Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) has announced a global exclusive Memorandum of Understanding (MOU)with Alstom (EPA: ALO) to jointly develop and commercialize graphene-enhanced HVAC products for the global rail industry.The agreement represents major commercial validation for GMG, providing the company with an exclusive opportunity to work alongside one of the world's largest rail manufacturers. Alstom operates in 61 countries, employs approximately 87,800 people, and generated 19.2 billion in annual revenue, giving GMG exposure to a global transportation infrastructure market.
The collaboration is expected to evaluate graphene technologies designed to improve energy efficiency, thermal performance, equipment durability, and operating reliability across rail HVAC systems.
Alongside Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF), investors are also monitoring trading activity in NOVAGOLD Resources Inc. (NYSE: NG) (TSX: NG), B2Gold Corp. (TSX: BTO) (NYSE: BTG), Denison Mines Corp. (TSX: DML) (NYSE: DNN), and Vivakor, Inc. (NASDAQ: VIVK), as investor interest continues building across advanced materials, critical minerals, clean energy, and infrastructure-focused growth companies.
The announcement further strengthens GMG's growing commercialization momentum following record June sales orders, completion of its Generation 2.0 Graphene Manufacturing Plant, and expanding adoption of its graphene technologies across HVAC, industrial cooling, AI data centers, and commercial infrastructure.For investors, the exclusive relationship with Alstom could serve as an important long-term catalyst by expanding GMG's addressable market, increasing commercial credibility, validating its proprietary graphene technology with a global industry leader, and creating potential opportunities for future revenue growth if commercial deployment advances successfully
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=graphene-manufacturing-tsxv-gmg-otcqx-gmgmf-signs-exclusive-global-rail-agreement-with-alstom]
Country: United States
Website: http://www.thestreetreports.com
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Graphene Manufacturing (TSXV: GMG) (OTCQX: GMGMF) Signs Exclusive Global Rail Agreement with Alstom here
News-ID: 4585245 • Views: …
More Releases from ABNewswire
Precision Biotics Market Projected to Reach $9.26 billion by 2031 | Top Companie …
Precision Biotics Market by Type (Precision Probiotics, Next-generation Probiotics, Synbiotics, Postbiotics), End-use Industry, Health/Functional Positioning, Distribution Channel, and Region - Global Forecast to 2031
The precision biotics market [https://www.marketsandmarkets.com/Market-Reports/precision-biotics-market-110337959.html] is projected to grow from USD 4.91 billion in 2026 to reach USD 9.26 billion by 2031, at a Compound Annual Growth Rate (CAGR) of 13.5% during the forecast period. The global precision biotics market is experiencing steady growth. This can be…
NLP in Healthcare & Life Sciences Market to Surge to USD 30.06 Billion by 2031, …
NLP in Healthcare & Life Sciences Market by Offering (Software, Services), Technology (Rule-based & Symbolic NLP, Statistical & Classical Machine Learning NLP), End User (Healthcare Providers, Healthcare Payers) - Global Forecast to 2031.
According to MarketsandMarkets Trademark , the NLP in Healthcare & Life Sciences market [https://www.marketsandmarkets.com/Market-Reports/healthcare-lifesciences-nlp-market-131821021.html?utm_source=abnewswire.com&utm_medium=referral&utm_campaign=healthcarelifesciencesnlpmarket] size was valued at USD 5.92 billion in 2025 and is projected to grow from USD 8.14 billion in 2026 to USD 30.06 billion…
Tech Stocks LABT, ANY, INLF, GMGMF, ZCMD Under $2 Watch Now
As investors continue searching for emerging growth opportunities, several technology, biotechnology, healthcare, industrial automation, and digital infrastructure companies trading under $2 are attracting attention following recent corporate developments spanning Artificial Intelligence (AI), AI Infrastructure, Robotics, Healthcare Technology, Graphene, and Advanced Manufacturing.
Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT) continues advancing its proprietary antimicrobial platform as global concern surrounding antimicrobial resistance (AMR) intensifies. The Company recently reported new laboratory data supporting its Phase 2-ready…
Vertos Market Launches New Marketplace to Help Founders Turn Digital Projects In …
The new platform connects buyers and sellers of AI-built businesses, SaaS products, websites, and digital assets, creating new opportunities for entrepreneurs and investors.
Image: https://www.abnewswire.com/upload/2026/07/c99232418e609205f2ae32e502ce78f4.jpg
July 23, 2026 - The rapid rise of artificial intelligence has transformed the way software is created. Tasks that once required months of development can now be completed in weeks or even days, enabling entrepreneurs to launch websites, SaaS platforms, mobile apps, AI tools, Chrome extensions, and…
More Releases for GMG
Which Companies Lead the Generalized Myasthenia Gravis Treatment (gMG) Market in …
DataM Intelligence has published its latest research report, "Generalized Myasthenia Gravis Treatment Market Size 2026." The report provides comprehensive analysis of market dynamics, including regional growth patterns, segment-wise performance, CAGR forecasts, competitive positioning, and revenue trends across key industry participants. It also examines the major factors influencing market expansion, emerging business opportunities, and strategic developments. Designed to support informed business planning, the study delivers a clear assessment of market value,…
Graphene Manufacturing (TSXV: GMG) (OTCQX: GMGMF) CEO Discusses Commercial Graph …
Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) continues to build momentum as the company expands production, secures new commercial partnerships, and advances the commercialization of its graphene technology platform. Founder and CEO Craig Nicol recently appeared on CEO.CA to discuss GMG's growing ability to manufacture and sell its expanding portfolio of graphene-based products. Watch the interview Now! [https://youtu.be/BV39Ikllstc]
GMG has evolved beyond the research stage and is increasingly focused on…
Dual-Listed Stocks GMG, AMLM, PNPN, BB in the U.S. and Canada to Watch
As investors continue searching for opportunities tied to critical minerals, energy efficiency, electrification, cybersecurity, artificial intelligence, and advanced manufacturing, several companies trading in both the United States and Canada are drawing increased attention. Among them are Graphene Manufacturing Group Ltd (TSXV: GMG) (OTCQX: GMGMF), American Lithium Minerals (OTC: AMLM), Power Metallic Mines Inc. (TSXV: PNPN) (OTCQB: PNPNF), and BlackBerry Limited (NYSE: BB) (TSX: BB).
Graphene Manufacturing Group (GMG) continues expanding its…
Generalized Myasthenia Gravis (gMG) Market Enters Strong Growth Nearly USD 3.2 b …
Generalized Myasthenia Gravis (gMG) Market Enters Strong Growth Phase with Breakthrough Biologic Therapies
Snippet / Teaser:
The global Generalized Myasthenia Gravis (gMG) market is witnessing accelerated growth as awareness improves, advanced biologic therapies gain adoption, and rare-disease healthcare infrastructure expands worldwide. With rising diagnosis rates and strong therapy pipelines, gMG is emerging as a high-value segment in autoimmune and neuromuscular disorder treatment.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/72089
1. Keyword Definition…
Generalized Myasthenia Gravis (gMG) Market is expected to reach $9.8 billion by …
Generalized myasthenia gravis (gMG) is a rare, chronic autoimmune neuromuscular disorder characterized by muscle weakness, fatigue, and impaired communication between nerves and muscles. It is caused by autoantibodies-primarily against acetylcholine receptors (AChR) or muscle-specific kinase (MuSK)-that disrupt neuromuscular transmission. gMG significantly impacts patients' quality of life, often leading to difficulties in mobility, vision, swallowing, and breathing.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72089
Historically, treatment revolved around acetylcholinesterase inhibitors…
Generalized Myasthenia Gravis (gMG) market dynamics are anticipated to change by …
The generalized myasthenia gravis (gMG) market dynamics are anticipated to change in the coming years owing to the expected approval of emerging therapies focused on treating gMG during the forecast period of 2021‒2034. There are presently a few key players in the gMG market, including Alexion/Astrazeneca, argenx, UCB, Horizon, Roche, and others.
view detailed report here: https://olympusresearchglobal.com/report-detail/generalized-myasthenia-gravis-gmg-market-insights-epidemiology-market-forecast-2034/
Source: https://olympusresearchglobal.com/
View all Reports: https://olympusresearchglobal.com/report/
The landscape of the generalized myasthenia gravis (gMG) market is poised…
